



mirror the well-established and highly reliable TNM classification used in oncology.<sup>7</sup> The ATN considers the three main components of PM: chorioretinal atrophy (A), myopic traction maculopathy (T), and myopic choroidal neovascularization (N).<sup>8</sup> International validation studies have shown good intra- and interobserver correlation for all three components, demonstrating that the ATN is a reliable and highly reproducible classification method.<sup>9</sup> More recently, a large study has successfully applied the ATN system to grade myopic maculopathy.<sup>10</sup>

High myopia is commonly defined as a spherical equivalent of  $> -6.0$  diopters (D) or an axial length (AL) of  $\geq 26.0$ ,<sup>11,12</sup> although some authors set the threshold at  $> -8.0$  D.<sup>5</sup> Actually, PM was first defined by Curtin in 1977,<sup>13</sup> but—like high myopia—the definition proposed by Curtin is not without controversy. The first definition of PM was based on changes leading to vision loss in long, highly myopic eyes.<sup>14,15</sup> Although AL does seem to play a role in myopic maculopathy,<sup>16</sup> there are reports of emmetropic eyes showing posterior staphyloma- and myopia-related alterations.<sup>17</sup> Ohno-Matsui et al proposed that PM be defined as the presence of myopic maculopathy,<sup>18</sup> but no studies have been conducted till date to objectively correlate the presence of myopic morphological changes with visual acuity. According to the META-PM classification system, PM is defined as “the eyes having equal to or more serious than diffuse choroidal atrophy” or “the eyes having staphylomas.”<sup>19</sup> This was justified as categories A0, A1,

and A2, which do not imply significant vision loss. However, the precise point at which the T and N components are likely to compromise visual acuity remains undefined.

In this context, the aim of the present study was to evaluate the reliability of the ATN classification system in patients with severe PM by correlating the ATN grade with best-corrected visual acuity (BCVA). In addition, we aimed to establish a specific cutoff score for each component (atrophy, traction, and neovascularization) at which BCVA could be considered to be especially compromised.

## Methods

This was a retrospective review of 100 eyes of patients diagnosed with PM at Puerta de Hierro-Majadahonda University Hospital (Madrid, Spain). This study adhered to the tenets of the Declaration of Helsinki and was approved by the hospital ethics committee.

Inclusion criteria were as follows: spherical equivalent (SE)  $> -6.0$  D or  $> 26$  mm of AL and a score  $\geq 3$  on the ATN grading system. This latter criterion was included to ensure the inclusion of patients across the entire spectrum,<sup>8</sup> in part because the validation study for the ATN system was based on samples that skewed toward lower levels of PM on the ATN classification.<sup>9</sup> Exclusion criteria were the presence of any other ophthalmological or systemic disease or previous macular surgery.

All patients underwent a complete ophthalmological examination consisting of the following: BCVA (in logarithm of the minimum angle of resolution), optical biometry AL determination (IOL Master 500; Carl Zeiss, Germany), slit-lamp examination, Goldmann applanation tonometry, and multimodal imaging—fundus photography and swept-source optical coherence tomography (SS-OCT; Triton, Topcon, Co. Japan).

Five of the six retina specialists (J.R.M., I.F.-M., J.M.R.-M., K.O.-M., G.C., R.S.) involved in the original validation study of the ATN grading system graded the 100 patients in the present study (without any additional clinical data) using the updated version of the ATN classification (Table 1). Grading was based on fundus photography and two 12-mm, fovea-centered SS-OCT b-scans (vertical and horizontal), following the approach described in the validation study (Figure 1).<sup>9</sup> The grades were compared to determine interobserver agreement. The mean score for each component (A, T, and N) was calculated, and these values were then correlated with age, BCVA, and AL.

From the \*Department of Ophthalmology, Puerta de Hierro-Majadahonda University Hospital, Madrid, Spain; †Department of Ophthalmology and Visual Science at Tokyo Medical and Dental University, Tokio, Japan; ‡Singapore National Eye Centre, Singapore Eye Research Institute, Singapore; §Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, Coimbra, Portugal; ¶Ophthalmology Department, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal; \*\*Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal; ††Association for Innovation and Biomedical Research on Light and Image (AIBILD), Coimbra, Portugal; ‡‡Department of Ophthalmology, Castilla La Mancha University, Albacete, Spain; §§Vissum Corporation, Spain; and ¶¶Red Temática de Investigación Cooperativa en Salud, “Prevención, detección precoz, y tratamiento de la patología ocular prevalente, degenerativa y crónica” (RD16/0008/0021), Spanish Ministry of Health, Instituto de Salud Carlos III, Madrid, Spain.

None of the authors has any financial/conflicting interests to disclose.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Reprint requests: Jorge Ruiz-Medrano, MD, PhD, 38 Melendez Valdes, 28015 Madrid, Spain; e-mail: jorge.ruizmedrano@gmail.com

Table 1. Updated ATN Classification System

| Atrophic Component (A)  | Tractional Component (T)   | Neovascular Component (N)                            |
|---|--|--|
| A0: No myopic retinal lesions<br>A1: Tessellated fundus only  | T0: no macular schisis<br>T1: inner or outer foveoschisis OR<br><i>lamellar macular hole</i>   | N0: no myopic CNV<br>N1: lacquer cracks              |
| A2: Diffuse chorioretinal atrophy<br><b>A3: Patchy chorioretinal atrophy</b><br><b>A4: Complete macular atrophy</b> | T2: inner + outer foveoschisis<br><b>T3: foveal detachment</b><br><b>T4: full-thickness macular hole</b><br><b>T5: macular hole + retinal detachment</b> | <b>N2a: active CNV</b><br><b>N2s: scar/Fuch spot</b> |

New update based on the original ATN grading system from Ruiz-Medrano J. *Prog Retin Eye Res* 2019;69:80–115.  
 Bold-italic: stages that define severe pathologic myopia.

**Statistical Analysis**

The statistical analyses were performed with SPSS for Windows, v.24.0 (IBM-SPSS, Chicago, IL) and Stata, v15.1 (StataCorp LLC, College Station, TX). Descriptive statistics were performed for all variables. Interobserver agreement was analyzed using Fleiss kappa statistics. The kappa statistic (k) was considered “moderate” if  $k > 0.4$ , “good” if  $k > 0.6$ , and “excellent” if  $k > 0.8$ . Bivariate correlations were evaluated using Spearman correlation coefficient. Student *t* test was used to compare groups when the data were normally distributed or the Mann–Whitney test for non-parametric tests. A *P* value of  $<0.05$  was considered statistically significant.

**Results**

One-hundred eyes (53 left) from 91 patients (78 women) were classified. All eyes scored  $\geq 3$  on the ATN. Mean patient age was  $65.1 \pm 11.7$  years (range, 36–97 years). Mean BCVA was  $-0.63 \pm 0.62$  ( $-3.00-0.00$ ), and mean AL  $29.26 \pm 2.7$  mm (range, 26.01–37.66 mm).

The mean ATN grade (Table 2) for each component was as follows: A =  $2.51 \pm 0.78$  (range, 0.6–4.0), T =  $0.88 \pm 1.14$  (range, 0.0–5.0), and N =  $1.31 \pm 1.40$  (range, 0.0–3.0). The mean interobserver agreement for all graders was 77.0% (Table 3); by component, agreement was 74.2% (A), 77.6% (T), and 79.2% (N), respectively. The weighted Fleiss kappa (k) statistic (adjusted by the quadratic weight for disagreement) was excellent for all three categories, with correlations

(k value) of 0.802 (A), 0.891 (T), and 0.850 (N), with interobserver agreement rates of 98.1%, 98.7% and 94.6%, respectively.


Intergrader agreement for each variable is shown in Table 4. The weakest agreement for all three components was observed in stages A1, T0, and N1, with correlation values of 0.366, 0.704, and 0.394, respectively. Correlation was good or excellent for all of the other stages, ranging from 0.615 to 0.926.

The bivariate analysis to determine correlation between the mean grade on each individual component (A/T/N) and age, BCVA, and AL showed a significant negative correlation (Spearman correlation test) between BCVA and A ( $r = -0.259$ ,  $P < 0.01$ ) and N ( $r = -0.23$ ,  $P = 0.02$ ) scores (Table 5). Axial length and T values were also significantly and positively correlated ( $r = 0.67$ ,  $P = 0.01$ ).

Patients with A score of  $\geq 3$  and/or T of  $\geq 3$  and/or N of  $\geq 2$  presented significantly worse BCVA. No between-group differences in age were observed. Axial length was significantly different in eyes with T score of  $< 3$  versus those of  $\geq 3$ . There was no difference in AL between groups according to A and N (Table 6).

**Discussion**

In this study, patients presenting signs of advanced PM were classified using the criteria in the updated version of the ATN grading system, which now incorporates additional features, such as lamellar macular hole to improve the accuracy of the classification. A total of five specialists classified 100 eyes according to ATN criteria. Overall, the mean weighted interobserver agreement was



**Fig. 1.** Highly myopic patient showing a complete macular atrophy, inner and outer foveoschisis and a choroidal neovascularization scar (A4T2N2s).

Table 2. Demographics. Mean ATN Values

| Variable      | n   | Mean  | Standard Deviation | Minimum | Maximum |
|---------------|-----|-------|--------------------|---------|---------|
| Age, years    | 100 | 65.12 | 11.72              | 36      | 97      |
| BCVA (logMAR) | 100 | -0.63 | 0.62               | -3.00   | 0.00    |
| AL            | 74  | 29.26 | 2.7                | 26.01   | 37.66   |
| Mean A        | 100 | 2.51  | 0.78               | 0.60    | 4.0     |
| Mean T        | 100 | 0.88  | 1.14               | 0.00    | 5.0     |
| Mean N        | 100 | 1.31  | 1.4                | 0.00    | 3.0     |

LogMAR, logarithm of the minimum angle of resolution.

97.1%, with Fleiss correlations (k) of 0.802 (A), 0.891 (T), and 0.850 (N). Interobserver agreement rates were 98.1%, 98.7%, and 94.6%, respectively. In eyes with severe PM, BCVA was significantly worse with longer AL, in eyes graded as ≥A3 and/or T3. The good interobserver correlation demonstrated in the present study confirms the reliability of the ATN grading system.

The establishment of an accepted and reliable grading system for PM is paramount to guarantee an accurate and homogenous classification and follow-up of patients in daily retina consultations, scientific publications, and most importantly, clinical trials. For this reason, our group developed the original ATN grading system for PM in 2018.<sup>8</sup> This system is modeled on the widely used TNM classification system commonly used to grade cancer.<sup>7</sup> The ATN grading system uses three letters and three numbers to grade each component, thus providing a straightforward classification of patients with PM. The reliability of the ATN system was evaluated in a previous study involving retina specialists from various countries. The excellent results of that study in terms of both intra- and interobserver correlation support the use of the ATN system.<sup>9</sup> Other groups have also used this scale to reliably classify patients with PM, with one study classifying more than 1,000 eyes.<sup>10</sup>

Although the concept of PM has not yet been clearly defined, there does seem to be general agreement regarding the changes in highly myopic eyes that lead to vision loss. In fact, in the study by Ohno-Matsui et al,<sup>19</sup>

Table 3. Intergrader Agreement

| Variable     | % Agreement | k     | 95% CI      |
|--------------|-------------|-------|-------------|
| Atrophic*    | 74.2        | 0.619 | 0.542–0.696 |
| Traction*    | 77.6        | 0.660 | 0.584–0.736 |
| Neovascular* | 79.2        | 0.693 | 0.631–0.756 |
| Atrophic†    | 98.1        | 0.802 | 0.745–0.858 |
| Traction†    | 98.7        | 0.891 | 0.831–0.950 |
| Neovascular† | 94.6        | 0.850 | 0.782–0.917 |

CI, confidence interval.

\*Fleiss kappa statistic, without weights.

†Fleiss kappa statistic, with weights. Quadratic weight for disagreement: weights are defined as  $1 - (k - l)^2 / (q_{max} - q_{min})^2$ , where k and l refer to the actual ratings and  $q_{max}$  and  $q_{min}$  are the maximum and minimum of all observed ratings.

the presence of diffuse choroidal atrophy (Stage A2 in the ATN system) was defined as the point beyond which visual acuity is considered severely compromised.<sup>3</sup> Although posterior staphyloma is not the primary defect in PM, it can lead to important posterior pole alterations and an increased prevalence of atrophic<sup>20</sup> and tractional aggression,<sup>21</sup> together with a lower BCVA when compared with eyes without posterior staphyloma.<sup>22</sup>

Axial length and age should not be overlooked in these patients because both variables (i.e., longer AL and older age) seem to increase the odds of progression in eyes with posterior staphyloma<sup>23</sup> and PM-related alterations in the posterior pole.<sup>24</sup> In fact, the prevalence of posterior staphyloma—which is low in young, highly myopic patients—is greater than 53% in patients older than 60 years.<sup>13</sup> Lamellar macular hole was not included in the original version of the ATN classification, but because of the potential for lamellar macular hole to negatively impact BCVA and given its association with AL, its presence must be considered. Consequently, the updated version of the ATN classification now includes lamellar macular hole (T1 on the ATN

Table 4. Intergrader Agreement

| Variable Atrophic    | n  | K     |
|----------------------|----|-------|
| 1                    | 8  | 0.366 |
| 2                    | 43 | 0.615 |
| 3                    | 41 | 0.719 |
| 4                    | 8  | 0.654 |
| Variable Traction    | n  | k     |
| 0                    | 45 | 0.704 |
| 1                    | 31 | 0.714 |
| 2                    | 15 | 0.843 |
| 3                    | 3  | 0.926 |
| 4                    | 4  | 0.913 |
| 5                    | 2  | 0.907 |
| Variable Neovascular | N  | K     |
| 0                    | 41 | 0.816 |
| 1                    | 5  | 0.394 |
| 2a                   | 24 | 0.665 |
| 2s                   | 30 | 0.646 |

Fleiss kappa statistic.

Table 5. Bivariate Analysis

| Grading     | Variable | Correlation | P*    |
|-------------|----------|-------------|-------|
| Atrophy     | Age      | 0.102       | 0.312 |
|             | BCVA     | -0.259      | 0.009 |
|             | AL       | 0.226       | 0.100 |
| Traction    | Age      | 0.018       | 0.860 |
|             | BCVA     | -0.046      | 0.653 |
|             | AL       | 0.670       | 0.010 |
| Neovascular | Age      | 0.029       | 0.776 |
|             | BCVA     | -0.230      | 0.021 |
|             | AL       | -0.113      | 0.418 |

\*Spearman's correlation test.

scale).<sup>25</sup> Some published reports refer to the concept of “extreme myopia,” defined as a clear surgical scope with an AL of >30 mm in patients whose surgical outcomes are worse than eyes with a shorter axial length (≤30 mm).<sup>22</sup> Nonetheless, the degree of traction associated with a possible loss of BCVA remains unclear.

Given this background, we performed the current study to assess the possible association between ATN grade and three variables (age, AL, and BCVA). Surprisingly, we did not find, despite our expectations, a statistically significant correlation between age and ATN grade, in contrast to previous reports.<sup>20,26,27</sup> This unexpected finding is probably the result of the study inclusion criteria, which required a combined ATN score of ≥3 and to the relatively high mean age of our cohort (the youngest patient was 36 years old). There was a negative correlation between BCVA and the ATN score for A and N, and AL positively correlated with T.

Considering our results in the context of previous research, we reached a consensus agreement to define severe PM as a score of ≥3 points on the A or T component and/or ≥2 on the N component, which we denominated a “significant myopic macular complication.” Patients with severe PM presented significantly worse BCVA than those with common PM, defined by any of the three components of the ATN grading system (Table 6). Similarly, AL was significantly longer in patients with severe PM versus those with common PM (defined by the tractional component), although there were no differences in AL in patients with significant myopic macular complications, defined by either A or N. These findings are consistent with previous reports describing a positive correlation between myopic traction maculopathy and AL<sup>21,26,27</sup> and between the absence of a significant correlation between AL and myopic choroidal neovascularization (CNV), where a preserved choriocapillary is theoretically needed for the CNV complex to develop.<sup>28</sup> This finding raises questions about the true etiology of “myopic CNV,” given that CNV resulting from other causes (such as punctate inner choroidopathy or idiopathic CNV) may be included in this category. More data are needed to reach more definitive conclusions regarding the origin of CNV in myopic eyes (our sample included four cases with a grade of N2 and A <2). For this reason, we suggest that only the A and T components of the ATN be considered when defining severe PM, at least until the definition of myopic CNV has been firmly established, which we expect will exclude cases of CNV with a low A component.

Table 6. Pathologic Myopia vs. Severe Pathologic Myopia Comparison

| Grading     | Variable      | PM                    | Severe PM             | P*    |
|-------------|---------------|-----------------------|-----------------------|-------|
| Atrophy     | Age, years    | n: 54<br>63.8 ± 11.6  | n: 46<br>66.5 ± 11.8  | 0.19  |
|             | BCVA (logMAR) | n: 54<br>-0.52 ± 0.55 | n: 46<br>-0.76 ± 0.68 | 0.02  |
|             | AL            | n: 41<br>29.2 ± 2.7   | n: 33<br>29.1 ± 2.3   | 0.49  |
| Traction    | Age, years    | n: 92<br>65.0 ± 12.0  | n: 8<br>65.8 ± 2.3    | 0.78  |
|             | BCVA (logMAR) | n: 92<br>-0.61 ± 0.63 | n: 8<br>-0.91 ± 0.52  | 0.02  |
|             | AL            | n: 66<br>28.8 ± 2.4   | n: 8<br>32.3 ± 1.0    | 0.01  |
| Neovascular | Age, years    | n: 55<br>64.1 ± 11.3  | n: 45<br>66.2 ± 12.1  | 0.21  |
|             | BCVA (logMAR) | n: 55<br>-0.54 ± 0.60 | n: 45<br>-0.75 ± 0.64 | 0.02  |
|             | AL            | n: 37<br>30.2 ± 2.6   | n: 37<br>28.1 ± 1.9   | 0.051 |

logMAR, logarithm of the minimum angle of resolution.  
\*Mann-Whitney test.

The association between chorioretinal atrophy and AL remains controversial. Although some authors argue that chorioretinal atrophy is present in large posterior staphyloma,<sup>13,29,30</sup> the association between atrophy and AL remains unclear, as evidenced by our findings, which were not statistically significant.

### Study Strengths and Limitations

This study has several limitations. First, our sample did not include any patients younger than 36 years, which impeded our ability to assess the potential association between ATN grade and age. Moreover, the concept of myopic CNV remains undefined. In this regard, studies that include a wider range of age spans are needed. Although the present study had a larger sample size than the original validation study (100 vs. 60 eyes), larger studies would help to confirm the results obtained.

In conclusion, the findings of this study show that the updated ATN grading system is a simple, accurate, and reliable tool to classify patients with PM, with a strong interobserver correlation. Our results seem to support the definition of significant myopic macular complications in severe PM for patients with a grade of  $\geq$ A3 and/or T3 on the ATN classification system because these patients present significantly worse BCVA than those with lower (better) ATN grades.

**Key words:** myopic maculopathy, myopic traction maculopathy, myopic choroidal neovascularization, myopic atrophy, ATN classification.

### Acknowledgments

Bradley Londres: Providing language help.

### References

- Koh V, Yang A, Saw SM, et al. Differences in prevalence of refractive errors in young asian males in Singapore between 1996–1997 and 2009–2010. *Ophthalmic Epidemiol* 2014;21:247–255.
- Lee JH, Jee D, Kwon JW, Lee WK. Prevalence and risk factors for myopia in a rural Korean population. *Investig Ophthalmol Vis Sci* 2013;54:5466–5470.
- Morgan IG, Ohno-Matsui K, Saw SM. Myopia. *The Lancet* 2012;379:1739–1748.
- Iwase A, Araie M, Tomidokoro A, et al. Prevalence and causes of low vision and blindness in a Japanese adult population. The Tajimi Study. *Ophthalmology* 2006;113:1354–1362.e1.
- Shimada N, Tanaka Y, Tokoro T, Ohno-Matsui K. Natural course of myopic traction maculopathy and factors associated with progression or resolution. *Am J Ophthalmol* 2013;156:948–957.e1.
- Ohno-Matsui K, Kawasaki R, Jonas JB, et al. International photographic classification and grading system for myopic maculopathy. *Am J Ophthalmol* 2015;159:877–883.e7.
- Gospodarowicz MK, Miller D, Groome PA, et al. The process for continuous improvement of the TNM classification. *Cancer* 2004;100:1–5.
- Ruiz-Medrano J, Montero JA, Flores-Moreno I, et al. Myopic maculopathy: current status and proposal for a new classification and grading system (ATN). *Prog Retin Eye Res* 2019;69:80–115.
- Ruiz-Medrano J, Flores-Moreno I, Ohno-Matsui K, et al. Validation of the recently developed atn classification and grading system for myopic maculopathy. *Retina* 2020;40:2113–2118.
- Chen Q, He J, Hu G, et al. Morphological characteristics and risk factors of myopic maculopathy in an older high myopia population—based on the new classification system (ATN). *Am J Ophthalmol* 2019;208:356–366.
- Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. *Ophthalmology* 2014;121:682–692.
- Ohno-Matsui K. What is the fundamental nature of pathologic myopia? *Retina* 2017;37:1043–1048.
- Curtin BJ. The posterior staphyloma of pathologic myopia. *Trans Am Ophthalmol Soc* 1977;75:67–86.
- Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. *Ophthalmology* 2016;123:1036–1042.
- Tokoro T. On the definition of pathologic myopia in group studies. *Acta Ophthalmol* 1988;66:107–108.
- Moriyama M, Ohno-Matsui K, Hayashi K, et al. Topographic analyses of shape of eyes with pathologic myopia by high-resolution three-dimensional magnetic resonance imaging. *Ophthalmology* 2011;118:1626–1637.
- Wang NK, Wu YM, Wang JP, et al. Clinical characteristics of posterior staphylomas in myopic eyes with axial length shorter than 26.5 millimeters. *Am J Ophthalmol* 2016;162:180–190.
- Du R, Fang Y, Jonas J, et al. Clinical features of patchy chorioretinal atrophy in pathologic myopia. *Retina* 2020;40:951–959.
- Ohno-Matsui K, Lai TY, Lai CC, Cheung CM. Updates of pathologic myopia. *Prog Retin Eye Res* 2016;52:156–187.
- Ohno-Matsui K. Proposed classification of posterior staphylomas based on analyses of eye shape by three-dimensional magnetic resonance imaging and wide-field fundus imaging. *Ophthalmology* 2014;121:1798–1809.
- Baba T, Ohno-Matsui K, Futagami S, et al. Prevalence and characteristics of foveal retinal detachment without macular hole in high myopia. *Am J Ophthalmol* 2003;135:338–342.
- Ma J, Li H, Ding X, et al. Effectiveness of combined macular buckle under direct vision and vitrectomy with ILM peeling in refractory macular hole retinal detachment with extreme high axial myopia: a 24-month comparative study. *Br J Ophthalmol* 2017;101:1386–1394.
- Gözüm N, Çakir M, Gücükoglu A, Sezen F. Relationship between retinal lesions and axial length, age and sex in high myopia. *Eur J Ophthalmol* 1997;7:277–282.
- Chen SJ, Cheng CY, Li AF, et al. Prevalence and associated risk factors of myopic maculopathy in elderly Chinese: the Shihpai eye study. *Investig Ophthalmol Vis Sci* 2012;53:4868–4873.
- dell’Omo R, Virgili G, Bottoni F, et al. Lamellar macular holes in the eyes with pathological myopia. *Graefes Arch Clin Exp Ophthalmol* 2018;256:1281–1290.
- Benhamou N, Massin P, Haouchine B, et al. Macular retinoschisis in highly myopic eyes. *Am J Ophthalmol* 2002;133:794–800.

27. Hiraakata A, Hida T. Vitrectomy for myopic posterior retinoschisis or foveal detachment. *Jpn J Ophthalmol* 2006;50:53–61.
28. Cheung CM, Arnold JJ, Holz FG, et al. Myopic choroidal neovascularization: review, guidance, and consensus statement on management. *Ophthalmology* 2017;124:1690–1711.
29. Steidl SM, Pruett RC. Macular complications associated with posterior staphyloma. *Am J Ophthalmol* 1997;123:181–187.
30. Blach R, Jay B, Macfaul P. The concept of degenerative myopia. *Proc R Soc Med* 1965;58:109–112.